<p>Sight Sciences（納斯達克代碼：SGHT - 獲取免費報告）於週三發佈了其財報。公司報告本季度每股收益為（$0.24），低於市場共識預期的（$0.19），差距為（$0.05），FiscalAI 報道。Sight Sciences 的淨利潤率為負 49.67%，股本回報率為負 55.72%。該公司本季度的收入為 1970 萬美元，而市場共識預期為 1847 萬美元。</p>
<p>獲取 <strong>Sight Sciences</strong> 的提醒：</p>
<h2>Sight Sciences 股價下跌 0.7%</h2>
<p>週三交易時段，納斯達克 SGHT 股價下跌 $0.03，報 $4.30。該公司股票交易量為 183,982 股，而其平均交易量為 316,939 股。該股票的 50 日簡單移動平均為$4.09，200 日簡單移動平均為$5.83。Sight Sciences 的 1 年最低價為$2.81，最高價為$9.24。該公司的市值為$2.3392 億，市盈率為-5.73，貝塔值為 2.38。公司當前比率為 10.22，速動比率為 9.52，債務與股本比率為 0.63。</p>
<h2>內部人士下注</h2>
<p>在相關消息中，首席技術官 David Badawi 於 4 月 2 日星期四出售了 8,168 股公司的股票，交易價格為每股平均$3.48，總交易額為$28,424.64。出售完成後，首席技術官持有公司股票 1,990,290 股，價值$6,926,209.20。此交易代表其持股比例下降了 0.41%。該交易已在向 SEC 提交的文件中披露，文件可在 SEC 網站上查閲。此外，內部人士 Jeremy B. Hayden 於 4 月 6 日星期一出售了 13,761 股公司的股票，交易價格為每股平均$3.55，總價值為$48,851.55。出售後，該內部人士直接持有公司股票 369,770 股，價值$1,312,683.50。這代表其持股比例下降了 3.59%。該交易的披露信息可在 SEC 文件中找到。該交易是在預先安排的 10b5-1 交易計劃下執行的。在過去的九十天裏，內部人士共出售了 61,273 股公司股票，價值$221,764。公司內部人士持有公司股票的 28.90%。</p>
<h2>機構投資者對 Sight Sciences 的看法</h2>
<p>幾家大型投資者最近增加或減少了對 SGHT 的持股。Integral Health Asset Management LLC 在第四季度收購了 Sight Sciences 的新股份，價值約$3,370,000。Invesco Ltd.在第四季度收購了 Sight Sciences 的新股份，價值約$2,791,000。Walleye Capital LLC 在第四季度收購了 Sight Sciences 的新股份，價值約$2,332,000。Informed Momentum Co LLC 在第四季度收購了 Sight Sciences 的新股份，價值約$1,299,000。最後，Millennium Management LLC 在第四季度將其在 Sight Sciences 的持股增加了 99.4%。Millennium Management LLC 現在持有 266,919 股公司股票，價值$2,117,000，此前在該期間內又收購了 133,073 股。機構投資者和對沖基金持有公司 55.51% 的股份。</p>
<h2>華爾街分析師的看法</h2>
<p>一些股票分析師最近對 SGHT 股票發佈了報告。花旗集團將 Sight Sciences 的目標價從$9.10 下調至$6.50，並在 3 月 6 日的研究報告中對該公司給予了 “中性” 評級。Cantor Fitzgerald 在 3 月 2 日的研究報告中對 Sight Sciences 設定了$8.00 的目標價。瑞銀集團將 Sight Sciences 的目標價從$12.00 下調至$11.00，並在 3 月 6 日的研究報告中對該公司給予了 “買入” 評級。Stifel Nicolaus 在 3 月 2 日的研究報告中將 Sight Sciences 的目標價從$6.00 上調至$8.00，並給予該股票 “買入” 評級。最後，Weiss Ratings 在 4 月 10 日的研究報告中重申了對 Sight Sciences 股票的 “賣出（d-）” 評級。五位分析師對該股票給予了買入評級，三位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，該公司的共識評級為 “持有”，平均目標價為$8.31。</p>
<p><strong>查看我們對 Sight Sciences 的最新分析</strong></p>
<h2>關於 Sight Sciences</h2>
<p>（獲取免費報告）</p>
<p>Sight Sciences, Inc 是一家醫療設備公司，專注於開發和商業化微創治療慢性眼病的產品。公司的旗艦產品包括 OMNI®外科系統，旨在解決眼睛自然排水通道中的多個阻力點，以降低青光眼患者的眼內壓，以及 TearCare®系統，這是一種可穿戴設備，通過針對性的熱脈衝治療來治療瞼板腺功能障礙和乾眼病。</p>
<p>自 2012 年成立並在納斯達克上市以來，Sight Sciences 一直追求將研究驅動的產品開發與直接銷售模式相結合的戰略。</p>
<h2>推薦故事</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Sight Sciences</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0dIVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0dIVA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Sight Sciences 嗎？</h2>
<p>在考慮 Sight Sciences 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就買入，以便在更廣泛的市場注意到之前……而 Sight Sciences 並不在名單上。</p>
<p>雖然 Sight Sciences 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

SGHT

美國醫藥設備 ETF - iShares

標普健康醫療設備 ETF - SPDR

<p>Sight Sciences (NASDAQ:SGHT) 發佈了季度財報，每股收益為（$0.24），低於預期的（$0.19）。收入為 1970 萬美元，超過了 1847 萬美元的預期。該公司的股本回報率為負的 55.72%，淨利潤率為負的 49.67%。股票下跌 0.7%，報 4.30 美元。最近的內部交易包括首席技術官 David Badawi 出售 8168 股，內部人士 Jeremy B. Hayden 出售 13761 股。機構投資者持有該公司 55.51% 的股份，分析師的評級意見不一，普遍持有評級，平均目標價為 8.31 美元</p>

<p>Sight Sciences (NASDAQ:SGHT - Get Free Report) posted its earnings results on Wednesday. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.05), FiscalAI reports. Sight Sciences had a negative net margin of 49.67% and a negative return on equity of 55.72%. The firm had revenue of $19.70 million during the quarter, compared to the consensus estimate of $18.47 million.</p>
<div class="lb-trans"><p>Sight Sciences（納斯達克代碼：SGHT - 獲取免費報告）於週三發佈了其財報。公司報告本季度每股收益為（$0.24），低於市場共識預期的（$0.19），差距為（$0.05），FiscalAI 報道。Sight Sciences 的淨利潤率為負 49.67%，股本回報率為負 55.72%。該公司本季度的收入為 1970 萬美元，而市場共識預期為 1847 萬美元。</p>
</div><p>Get <strong>Sight Sciences</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Sight Sciences</strong> 的提醒：</p>
</div><h2>Sight Sciences Trading Down 0.7%</h2>
<div class="lb-trans"><h2>Sight Sciences 股價下跌 0.7%</h2>
</div><p>NASDAQ SGHT traded down $0.03 during trading hours on Wednesday, hitting $4.30. 183,982 shares of the company's stock were exchanged, compared to its average volume of 316,939. The stock has a 50-day simple moving average of $4.09 and a 200 day simple moving average of $5.83. Sight Sciences has a 1-year low of $2.81 and a 1-year high of $9.24. The firm has a market cap of $233.92 million, a price-to-earnings ratio of -5.73 and a beta of 2.38. The company has a current ratio of 10.22, a quick ratio of 9.52 and a debt-to-equity ratio of 0.63.</p>
<div class="lb-trans"><p>週三交易時段，納斯達克 SGHT 股價下跌 $0.03，報 $4.30。該公司股票交易量為 183,982 股，而其平均交易量為 316,939 股。該股票的 50 日簡單移動平均為$4.09，200 日簡單移動平均為$5.83。Sight Sciences 的 1 年最低價為$2.81，最高價為$9.24。該公司的市值為$2.3392 億，市盈率為-5.73，貝塔值為 2.38。公司當前比率為 10.22，速動比率為 9.52，債務與股本比率為 0.63。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><p>In related news, CTO David Badawi sold 8,168 shares of the firm's stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $3.48, for a total transaction of $28,424.64. Following the completion of the sale, the chief technology officer owned 1,990,290 shares of the company's stock, valued at $6,926,209.20. This trade represents a 0.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Jeremy B. Hayden sold 13,761 shares of the firm's stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $3.55, for a total value of $48,851.55. Following the sale, the insider directly owned 369,770 shares of the company's stock, valued at $1,312,683.50. This represents a 3.59% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 61,273 shares of company stock worth $221,764. Company insiders own 28.90% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，首席技術官 David Badawi 於 4 月 2 日星期四出售了 8,168 股公司的股票，交易價格為每股平均$3.48，總交易額為$28,424.64。出售完成後，首席技術官持有公司股票 1,990,290 股，價值$6,926,209.20。此交易代表其持股比例下降了 0.41%。該交易已在向 SEC 提交的文件中披露，文件可在 SEC 網站上查閲。此外，內部人士 Jeremy B. Hayden 於 4 月 6 日星期一出售了 13,761 股公司的股票，交易價格為每股平均$3.55，總價值為$48,851.55。出售後，該內部人士直接持有公司股票 369,770 股，價值$1,312,683.50。這代表其持股比例下降了 3.59%。該交易的披露信息可在 SEC 文件中找到。該交易是在預先安排的 10b5-1 交易計劃下執行的。在過去的九十天裏，內部人士共出售了 61,273 股公司股票，價值$221,764。公司內部人士持有公司股票的 28.90%。</p>
</div><h2>Institutional Investors Weigh In On Sight Sciences</h2>
<div class="lb-trans"><h2>機構投資者對 Sight Sciences 的看法</h2>
</div><p>Several large investors have recently added to or reduced their stakes in SGHT. Integral Health Asset Management LLC acquired a new stake in Sight Sciences during the fourth quarter worth approximately $3,370,000. Invesco Ltd. acquired a new stake in Sight Sciences in the fourth quarter valued at approximately $2,791,000. Walleye Capital LLC acquired a new stake in Sight Sciences in the fourth quarter valued at approximately $2,332,000. Informed Momentum Co LLC acquired a new stake in Sight Sciences in the fourth quarter valued at approximately $1,299,000. Finally, Millennium Management LLC grew its stake in Sight Sciences by 99.4% in the fourth quarter. Millennium Management LLC now owns 266,919 shares of the company's stock valued at $2,117,000 after acquiring an additional 133,073 shares during the period. Institutional investors and hedge funds own 55.51% of the company's stock.</p>
<div class="lb-trans"><p>幾家大型投資者最近增加或減少了對 SGHT 的持股。Integral Health Asset Management LLC 在第四季度收購了 Sight Sciences 的新股份，價值約$3,370,000。Invesco Ltd.在第四季度收購了 Sight Sciences 的新股份，價值約$2,791,000。Walleye Capital LLC 在第四季度收購了 Sight Sciences 的新股份，價值約$2,332,000。Informed Momentum Co LLC 在第四季度收購了 Sight Sciences 的新股份，價值約$1,299,000。最後，Millennium Management LLC 在第四季度將其在 Sight Sciences 的持股增加了 99.4%。Millennium Management LLC 現在持有 266,919 股公司股票，價值$2,117,000，此前在該期間內又收購了 133,073 股。機構投資者和對沖基金持有公司 55.51% 的股份。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師的看法</h2>
</div><p>A number of equities analysts have recently issued reports on SGHT shares. Citigroup lowered their price objective on Sight Sciences from $9.10 to $6.50 and set a &#34;neutral&#34; rating for the company in a research report on Friday, March 6th. Cantor Fitzgerald set a $8.00 price objective on Sight Sciences in a research report on Monday, March 2nd. UBS Group lowered their price objective on Sight Sciences from $12.00 to $11.00 and set a &#34;buy&#34; rating for the company in a research report on Friday, March 6th. Stifel Nicolaus raised their price objective on Sight Sciences from $6.00 to $8.00 and gave the stock a &#34;buy&#34; rating in a research report on Monday, March 2nd. Finally, Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Sight Sciences in a research report on Friday, April 10th. Five analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of &#34;Hold&#34; and an average price target of $8.31.</p>
<div class="lb-trans"><p>一些股票分析師最近對 SGHT 股票發佈了報告。花旗集團將 Sight Sciences 的目標價從$9.10 下調至$6.50，並在 3 月 6 日的研究報告中對該公司給予了 “中性” 評級。Cantor Fitzgerald 在 3 月 2 日的研究報告中對 Sight Sciences 設定了$8.00 的目標價。瑞銀集團將 Sight Sciences 的目標價從$12.00 下調至$11.00，並在 3 月 6 日的研究報告中對該公司給予了 “買入” 評級。Stifel Nicolaus 在 3 月 2 日的研究報告中將 Sight Sciences 的目標價從$6.00 上調至$8.00，並給予該股票 “買入” 評級。最後，Weiss Ratings 在 4 月 10 日的研究報告中重申了對 Sight Sciences 股票的 “賣出（d-）” 評級。五位分析師對該股票給予了買入評級，三位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，該公司的共識評級為 “持有”，平均目標價為$8.31。</p>
</div><p><strong>View Our Latest Analysis on Sight Sciences</strong></p>
<div class="lb-trans"><p><strong>查看我們對 Sight Sciences 的最新分析</strong></p>
</div><h2>About Sight Sciences</h2>
<div class="lb-trans"><h2>關於 Sight Sciences</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company's flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye's natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.</p>
<div class="lb-trans"><p>Sight Sciences, Inc 是一家醫療設備公司，專注於開發和商業化微創治療慢性眼病的產品。公司的旗艦產品包括 OMNI®外科系統，旨在解決眼睛自然排水通道中的多個阻力點，以降低青光眼患者的眼內壓，以及 TearCare®系統，這是一種可穿戴設備，通過針對性的熱脈衝治療來治療瞼板腺功能障礙和乾眼病。</p>
</div><p>Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.</p>
<div class="lb-trans"><p>自 2012 年成立並在納斯達克上市以來，Sight Sciences 一直追求將研究驅動的產品開發與直接銷售模式相結合的戰略。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Sight Sciences</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Sight Sciences</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0dIVA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=SGHT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Sight Sciences Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Sight Sciences 嗎？</h2>
</div><p>Before you consider Sight Sciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Sight Sciences 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sight Sciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就買入，以便在更廣泛的市場注意到之前……而 Sight Sciences 並不在名單上。</p>
</div><p>While Sight Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Sight Sciences 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Sight Sciences（NASDAQ:SGHT）公佈季度財報結果